Posted by Michael Wonder on 27 Sep 2021
Will price of Avastin, staple in anti-cancer therapy, go down?
27 September 2021 - Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) inhibitor, is almost a staple in anticancer treatment combined with chemotherapy or immunotherapy in various types of cancer.
After Samsung Bioepis’ biosimilar of Avastin became reimbursable in Korea, the government notified that it would cut the price of Avastin by 30%.
